Editorial: Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: A debate over goals of research and an approach while the jury remains out

Annals of Surgical Oncology

Volumn 17, Issue 8, 2010, Pages 1983-1986

  Vauthey, Jean Nicolas ^a   Nordlinger, Bernard ^b   Kopetz, Scott ^a   Poston, Graeme ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b HÔPITAL AMBROISE PARÉ   (France)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ARTIFICIAL EMBOLISM; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOSURGERY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; EDITORIAL; FATTY LIVER; HUMAN; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; MEDICAL RESEARCH; MORBIDITY; PATIENT SAFETY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; RADIOFREQUENCY ABLATION; RECURRENCE RISK; STEATOSIS; SURVIVAL RATE; SURVIVAL TIME; COLORECTAL TUMOR; LIVER TUMOR; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954956609     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1007-2     Document Type: Editorial

References (28)

1. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715-24.
2. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-25.
3. Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-47.
4. Petrelli NJ. Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol. 2008;26:4862-3.
5. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-16.
6. Metreveli RE, Sahm K, Denstman F, et al. Hepatic resection at a major community-based teaching hospital can result in good outcome. Ann Surg Oncol. 2005;12:133-7.
7. Moertel CG, Fleming TR, Macdonald JS, et al. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol. 1993;11:2386-90.
8. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-72.
9. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845-53.
10. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118-24.
11. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983-90.
12. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1-7. (Pubitemid 43054046)
13. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052-61; discussion 1061-4.
14. Gruenberger T, Sorbye H, Debois M, et al (2006) Tumor response to preoperative chemotherapy with FOLFOX-4 for resectable colorectal cancer liver metastases. Interim results of EORTC Intergroup randomized phase III study 40983. J Clin Oncol 24:3500A.
15. Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008;26:5254-60.
16. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761-7.
17. Blazer DG III, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344-51.
18. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593-602.
19. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet. 2008;371:963-5.
20. Ribero D, Abdalla EK, Madoff DC, et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94:1386-94.
21. Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037-42.
22. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005;23:4853-5.
23. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304.
24. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302:2338-44.
25. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939-45.
26. Chun YS, Vauthey JN, Ribero D, et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007;11:1498-504.
27. Aloia TA, Vauthey JN, Loyer EM, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141:460-7.
28. Zalinski S, Abdalla EK, Mahvash A, et al. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol. 2009;16:1208-11.